St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
Also called: PHTS, Cowden syndrome, Cowden disease, Bannayan-Riley-Ruvalcaba syndrome, Proteus syndrome, Proteus-like syndrome, PTEN-related Proteus syndrome
PTEN hamartoma tumor syndrome is a genetic condition in which non-cancerous growths, called hamartomas, develop in different areas of the body. It can be passed down from parent to child (inherited). People with PTEN hamartoma tumor syndrome are at higher risk of developing cancers of the:
Along with hamartomas, patients can have other physical signs, including larger-than-average head size, abnormal skin growths, and problems with mental function and learning.
People with PTEN hamartoma tumor syndrome are at high risk for certain cancers. These cancers generally occur in adults who have the condition, not in children. The average age of cancer diagnosis is about 30–50 years old.
Thyroid cancer is the exception. It sometimes occurs in children with PTEN hamartoma tumor syndrome.
Type of Cancer | Lifetime Risk |
---|---|
Breast | 85% (in women) |
Thyroid | 35% |
Renal cell (kidney) | 35% |
Endometrium (lining of uterus) | 28% |
Colorectal | 9% |
Melanoma (skin cancer) | More than 5% |
People with PTEN hamartoma tumor syndrome rarely develop a type of brain tumor called cerebellar dysplastic gangliocytoma (also called adult-onset Lhermitte-Duclos disease). The exact risk of developing this type of tumor is unknown because it is so rare.
People with PTEN hamartoma tumor syndrome may have other physical signs besides the hamartomas. Not all people with this syndrome will have all of these.
Physical Signs | Estimated Risk |
---|---|
Larger-than-average head (macrocephaly) | 94% |
Skin growths or coloring: - Smooth, white skin growths on the face (trichilemmomas) - Smooth, flesh-colored skin growths on the hands or feet (acral or plantar keratosis) - Smooth skin growths in the mouth (oral papillomas) - Freckling of the penis skin in boys and men |
More than 90% |
Non-cancerous growths (polyps) in the digestive system | 90% |
Non-cancerous growths (nodules, goiter, adenoma) in the thyroid gland | 75% |
Non-cancerous growths (fibrocystic disease) in the breast | 67% |
Intellectual disability, learning disability, or autism spectrum disorder (learning problems) | 47-89% |
Other physical signs may include:
PTEN hamartoma tumor syndrome is caused by changes in a gene known as PTEN. Genes carry information telling cells within the body how to function. The PTEN gene helps control how and when cells grow, divide, and die.
Most people carry 2 working copies of the PTEN gene in their cells. One copy is inherited from the mother and 1 from the father. Cells from people with PTEN hamartoma tumor syndrome carry 1 working copy of PTEN and 1 copy that is changed. This change causes the gene to not work properly. It is called a PTEN mutation.
Between 10–50% of children with PTEN hamartoma tumor syndrome inherit the PTEN gene mutation from a parent who also has the syndrome. The rest have a new PTEN mutation that did not come from a parent.
Children with a new PTEN mutation have no history of the syndrome in their family. In these cases, the change either happened in an egg or sperm cell when the child was formed or in 1 of the child’s cells during pregnancy. These children are the first in their families to have PTEN hamartoma tumor syndrome.
No matter how it comes about, everyone with PTEN hamartoma tumor syndrome has a 50% (1 in 2) chance of passing it on to their children.
If the working copy (normal copy) of the PTEN gene undergoes changes within a cell, then that cell can begin to grow in an abnormal way. When both copies of the gene are changed, cancer can develop. That is why people with PTEN hamartoma tumor syndrome have a higher risk of cancer.
A health care provider may suspect that your child has PTEN hamartoma tumor syndrome after studying their medical and family cancer history.
This information helps the health care provider and the genetic counselor know if:
Your provider or genetics counselor may recommend PTEN genetic testing if they suspect PTEN hamartoma tumor syndrome.
Learn more about types of genetic tests.
A blood sample is sent to a genetic testing lab. The lab runs genetic tests that look for changes in the PTEN gene.
If your child has a PTEN mutation, a genetic counselor will:
Parents may choose to do prenatal testing to find out if a pregnancy is affected with a known PTEN mutation. Testing may take place either before pregnancy occurs or during pregnancy.
You should work with a genetic counselor to review the pros and cons of the test. The genetic counselor can also help you prepare for the test results.
Testing before pregnancy is called preimplantation genetic testing (PGT). This special type of genetic testing is done along with in vitro fertilization (IVF). PGT tests embryos for a known PTEN mutation before a provider places the embryo into the uterus.
Testing during pregnancy can help providers see if a pregnancy has a known PTEN mutation. A doctor gathers cells from the pregnancy in 1 of 2 ways:
After tissue collection, the lab checks the sample for the known PTEN mutation. Both tests carry minor risks. Discuss risks with an experienced health care provider or a genetic counselor.
Take time to think carefully about the benefits and risks of genetic testing. Speak with a genetic counselor before testing. If you decide to get tested, talk with your health care provider or a genetic counselor about your results so you can understand what they mean.
Sometimes, children or adults with PTEN hamartoma tumor syndrome feel sad, anxious, or angry after getting their test results. Parents may feel guilty if they pass the PTEN gene mutation to 1 or more of their children. People with a PTEN gene mutation may also have trouble getting disability or life insurance.
Read more about genetic discrimination.
People with the syndrome should be monitored and have follow-up with a health care provider who knows the condition well.
If a family member with PTEN hamartoma tumor syndrome was diagnosed with a certain type of cancer, then screening for other family members will likely happen sooner than described above. Health care providers usually start screening for that type of cancer at least 5 years before the earliest known diagnosis in the family. For example, if a family member with PTEN hamartoma tumor syndrome developed breast cancer at age 35, it is recommended that other family members with the syndrome start breast cancer screening at age 25–30.
It is possible that these recommendations may change over time as health care providers learn more about PTEN hamartoma tumor syndrome. Parents should discuss all screening options for their child with a health care provider who knows this syndrome well.
People of any age with PTEN hamartoma tumor syndrome have a higher risk of cancer. They should monitor their health and adopt healthy habits throughout life. It is important to continue to have regular physical checkups and screenings. The goal is to find any cancer early at the most treatable stage.
People should watch closely for signs or symptoms that could signal cancer:
Seek medical help if anything unusual appears.
Habits that will help you maintain a healthy lifestyle include:
The St. Jude Cancer Predisposition Program is dedicated to diagnosing and screening children with a genetic predisposition for cancer. Our program offers the best clinical care possible. We engage in cutting-edge research to gain more information about genetic disorders and cancer, and to improve the care and treatment for patients who are affected by these conditions. Learn more about the Division of Cancer Predisposition at St. Jude.
Our genetic counselors, clinicians, genetics nurse practitioners, and research assistants work together to provide patients with:
PTEN hamartoma tumor syndrome increases your child’s risk for cancer.
St. Jude offers clinical trials and cancer research studies for children, teens, and young adults who have cancers associated with PTEN hamartoma tumor syndrome.
Learn more about clinical research at St. Jude.
Study goal:
To learn more about participants beliefs, attitudes, and questions about gene therapy to help make web-based resources to share information. This could help patients make treatment decisions.
Age:
18 to 35 years old with rare genetic diseases
Study goal:
The main goal of this study is to learn more about the reasons childhood tumors form and how to treat them better.
Study goal:
To provide a high-quality repository of tumor and normal samples to facilitate translational research performed by St Jude faculty and their collaborators
Study goal:
1) Test each patient for hundreds of gene variations that might be important for drug use. All of the gene test results will be in the research laboratory, but as time goes on, the study will evaluate scientific evidence and selectively move test results for a few genes into the medical record if the evidence strongly shows that the result can help in better prescribing of drugs for patients; 2) Estimate how often pharmacogenetic test results are moved from research tests into a patient’s medical record; 3) Use methods to choose which of these tests should be put in the medical record; 4) Use computer-based tools in the electronic medical record to help doctors use gene test results when prescribing drugs; 5) Share feelings and concerns of patients and their families about gene test information being put in their medical record.
Study goal:
The main purpose of this trial is to learn about the genetic causes of cancer.
Age:
Younger than 50 years old
Study goal:
To collect data about how Friedreich’s ataxia progresses over time and affects the daily life of patients.
Age:
Any
Study goal:
To find out how much patients with hemophilia B, their caregivers, and health care workers know about gene therapy for this disease, and how they feel about gene therapy. This will help us better educate patients and caregivers about gene therapy for hemophilia B.
Age:
12 years and older
Patients accepted to St. Jude must have a disease we treat and must be referred by a physician or other qualified medical professional. We accept most patients based on their ability to enroll in an open clinical trial.
Call: 1-888-226-4343 (toll-free) or 901-595-4055 (local) | Fax: 901-595-4011 | Email: referralinfo@stjude.org | 24-hour pager: 1-800-349-4334
If you have questions about the Genetic Predisposition Clinic and care for PTEN hamartoma tumor syndrome, email our team at GPTeam@stjude.org.